Abstract:ID 95401 Poster Board 482 Objectives/Goals: Renal fibrosis is an outcome of chronic kidney disease that affects approximately one-tenth of the global community. Its pathogenesis and progression are highly multi-factorial, likely demanding a need to target various mechanisms for providing better treatment. Using an animal model of renal fibrosis, we sought to test the therapeutic response of TK-850, an experimental drug that acts as a dual-inhibitor of transforming growth factor beta receptor 1 (TGFβR1) and mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). Both serine/threonine kinases are associated with inducing pro-inflammatory and pro-fibrotic responses. Methods/Study Population: To assess the possible renal anti-fibrotic effects of TK-850, we performed a preclinical study using 8-10-week-old male and female C57BL/6 mice, who underwent unilateral ureteral obstruction (UUO) surgery for inducing renal fibrosis. Rodents either had UUO only (control), were administered TK-850 prior to and following UUO (UUO-P, 20 mpk/d/ip), or administered TK-850 following UUO (UUO-I, 20 mpk/d/ip). In either case, the kidneys and blood were collected ten days post-UUO for histopathological evaluation and biochemical analysis. Fibrosis of the kidneys was evaluated from renal hydroxyproline estimation and Picrosirius red stain for assessing collagen deposition. Results/Anticipated Results (700-character limit): As a result of UUO, both male and female mice showed similar renal hydroxyproline levels, 5.4 ± 0.41 μg/10mg, n = 5 and 5.5 ± 0.50 μg/10mg, n = 5, respectively, in comparison to the contralateral (control) kidney, 2.9 ± 0.14 μg/10mg, n = 10. Prophylactic and interventional administration of TK-850 significantly reduced hydroxyproline levels (UUO-P: 3.4 ± 0.24 μg/10mg, n = 10; UUO-I: 4.30 ± 0.20 μg/10mg, n = 10). Histological assessment of kidney injury (UUO) revealed increased collagen deposition (17.1 ± 0.43% collagen positive area, n = 10) in comparison to the non-injured, control kidney (2.0 ± 0.23%, n = 10). TK-850 treatment was also shown to significantly reduce collagen deposition in UUO-P (10.5 ± 0.38%, n = 10) and UUO-I (13.1 ± 0.25%, n = 10) mice. Both biochemical and histological responses with and without drug treatment were gender neutral. Discussion/Significance of Impact (300-character limit): In summary, our results show a positive effect of TK-850 administration to reduce kidney injury, supporting the notion of its use as a potential therapeutic compound. The results herein could also affirm the idea of having a concerted pharmacotherapeutic approach to treat such complex diseases. Research reported in this abstract was supported by a Post-Doctoral TL1 Award from National Institutes of Health under grant numbers TL1 TR003109 and UL1 TR003107.

Targeted inhibition of ZAK ameliorates renal interstitial fibrosis

Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis

14-3-3ζ inhibits maladaptive repair in renal tubules by regulating YAP and reduces renal interstitial fibrosis

FC 133: Knockout Of ZEB2 Ameliorates Progression of Renal Tubulointerstitial Fibrosis in a Mouse Model of Renal Ischemia-Reperfusion Injury

Enhancer of zeste homolog 2 promotes renal fibrosis after acute kidney injury by inducing epithelial-mesenchymal transition and activation of M2 macrophage polarization

Modified Zhenwu Tang delays chronic renal failure progression by modulating oxidative stress and hypoxic responses in renal proximal tubular epithelial cells

Role of Akt1 in renal fibrosis and tubular dedifferentiation during the progression of acute kidney injury to chronic kidney disease

Targeted Inhibition of Β-Catenin/cbp Signaling Ameliorates Renal Interstitial Fibrosis

Inhibition of PKC-δ retards kidney fibrosis via inhibiting cGAS-STING signaling pathway in mice

Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression.

Pharmacological Inhibition of STING/TBK1 Signaling Attenuates Myeloid Fibroblast Activation and Macrophage to Myofibroblast Transition in Renal Fibrosis

Targeting enhancer of zeste homolog 2 protects against acute kidney injury

Targeting NK-1R attenuates renal fibrosis via modulating inflammatory responses and cell fate in chronic kidney disease

Molecular mechanism of miR-382 in the pathogenesis of renal tubulointerstitial fibrosis

Targeting the transmembrane cytokine co-receptor neuropilin-1 in distal tubules improves renal injury and fibrosis

Shenkang Injection, a Modern Preparation of Chinese Patent Medicine, Diminishes Tubulointerstitial Fibrosis in Obstructive Nephropathy Via Targeting Pericyte-Myofibroblast Transition.

Reduction of Renal Interstitial Fibrosis by Targeting Tie2 in Vascular Endothelial Cells

The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation.

PDGFβ receptor-targeted delivery of truncated transforming growth factor β receptor type II for improving the in vitro and in vivo anti-renal fibrosis activity via strong inactivation of TGF-β1/Smad signaling pathway

Targeted VEGFA therapy in regulating early acute kidney injury and late fibrosis

Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGF{beta}R1/MAP4K4